Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression

JAMA Oncology

Volumn 2, Issue 9, 2016, Pages 1179-1186

  George, Saby ^a   Motzer, Robert J ^b   Hammers, Hans J ^c   Redman, Bruce G ^d   Kuzel, Timothy M ^e   Tykodi, Scott S ^f   Plimack, Elizabeth R ^g   Jiang, Joel ^h   Waxman, Ian M ^h   Rini, Brian I ⁱ  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g FOX CHASE CANCER CENTER   (United States)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; NIVOLUMAB;

ADULT; AGED; CARCINOMA, RENAL CELL; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SECONDARY; SURVIVAL RATE; TUMOR VOLUME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SURVIVAL RATE; TUMOR BURDEN;

EID: 85010416862     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.0775     Document Type: Article

References (28)

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer. Version 1.2016. NCCNWebsite. http://www .nccn.org/professionals/physician-gls/f-guidelines .asp. Accessed September 16, 2016.
2. Escudier B, Porta C, Schmidinger M, et al; ESMO GuidelinesWorking Group. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):iii49-iii56.
3. Raman R, Vaena D. Immunotherapy in metastatic renal cell carcinoma: a comprehensive review. Biomed Res Int. 2015;2015:367354.
4. Hudes G, Carducci M, Tomczak P, et al; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-2281.
5. Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360-3365.
6. Hamid O, Carvajal RD. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opin Biol Ther. 2013;13(6): 847-861.
7. Nurieva RI, Liu X, Dong C. Molecular mechanisms of T-cell tolerance. Immunol Rev. 2011;241(1):133-144.
8. Motzer RJ, Escudier B, McDermott DF, et al; CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803-1813.
9. Saenger YM,Wolchok JD. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun. 2008;8:1.
10. Hales RK, Banchereau J, Ribas A, et al. Assessing oncologic benefit in clinical trials of immunotherapy agents. Ann Oncol. 2010;21(10): 1944-1951.
11. Pennock GK,WaterfieldW,Wolchok JD. Patient responses to ipilimumab, a novel immunopoten tiator formetastatic melanoma: how different are these from conventional treatment responses? Am J Clin Oncol. 2012;35(6):606-611.
12. Hodi FS, Ribas A, Daud A, et al. Patterns of response in patients with advanced melanoma treated with pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC). J Immunother Cancer. 2014;2(suppl 3):poster P103.
13. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10): 1020-1030.
14. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-135.
15. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-330.
16. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-7420.
17. Finke LH,Wentworth K, Blumenstein B, Rudolph NS, Levitsky H, Hoos A. Lessons from randomized phase III studies with active cancer immunotherapies-outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine. 2007;25(suppl 2):B97-B109.
18. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
19. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33(31):3541-3543.
20. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab formetastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430-1437.
21. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. NCIWebsite. 2009. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf. Accessed September 16, 2015.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J AmStat Assoc. 1958;53(282):457-481.
23. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982;38 (1):29-41.
24. Clopper CJ, Pearson ES. The use of confidence of fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404-413.
25. Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010;102(18):1388-1397.
26. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847-856.
27. Kantoff PW, Halabi S, ConawayM, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17(8):2506-2513.
28. Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol. 1999;17 (6):1654-1663.